MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2022 International Congress

    Lateral shifting from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in the treatment of advanced idiopathic Parkinson’s disease (PD): Case series

    M. Abu Al-Melh, M. Farghal, N. Abdelall (Ahmadi governorate, Kuwait)

    Objective: To report our experience with transitioning from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in two patients with advanced idiopathic Parkinson’s disease (PD). Background: Device-assisted…
  • 2022 International Congress

    Modulation of the mesencephalic locomotor region activity during gait in parkinson’s disease patients

    Y. Mullie, J. Bourilhon, C. Olivier, A. Collomb-Clerc, K. Lehongre, N. Georges, C. Karachi, M. Welter (Paris, France)

    Objective: Deciphering the role of the MLR in gait and balance disorders in PD patients Background: Lesion or dysfunction of the MLR, including the Pedunculopontine…
  • 2022 International Congress

    Substantia nigra dopaminergic neuron density in PD, PSP and MSA: An interim clinicopathological analysis

    E. Backman, L. Saari, M. Gardberg, V. Kaasinen (Turku, Finland)

    Objective: To investigate substantia nigra pars compacta (SNc) area together with dopaminergic neuron count and density in atypical parkinsonisms in relation to Parkinson’s disease (PD)…
  • 2022 International Congress

    Comparison of different risk scores for Parkinson’s disease in a population-based 10-year study

    K. Marini, K. Seppi, S. Kiechl, H. Stockner, P. Willeit, J. Willeit, A. Djamshidian-Tehrani, G. Rungger, W. Poewe, P. Mahlknecht (Innsbruck, Austria)

    Objective: To validate the “enhanced” PREDICT-PD algorithm in a longitudinal population-based cohort and compare its performance with other Parkinson's disease risk scores in identifying cases…
  • 2022 International Congress

    Aerobic glycolysis regulates microglia-mediated neuroinflammation by promoting H3K9 lactylation in Parkinson’s disease

    Q. Qixiong, W. Hengming, W. Danlei, L. Jingyi, Q. Yi, Z. Jingwei, L. Jiangting (wuhan, China)

    Objective: This study aims to investigate the role of histone lactylation in microglia-mediated neuroinflammation and dopaminergic (DA) neuronal damage in Parkinson’s disease (PD). ​​​​​​​ Background: Augmented glycolysis induced by metabolic…
  • 2022 International Congress

    miR-218-5p Regulates Microglia-mediated Neuroinflammation through Type I Interferon Response in Parkinson’s Disease

    D. Wang, Q. Qin, J. Li, J. Zhao, Z. Mao, Z. Xue (Wuhan, China)

    Objective: To explore the effect of miR-218-5p on microglia activation and dopaminergic neurons damage in mice model of Parkinson's disease(PD) and its potential mechanisms. Background:…
  • 2022 International Congress

    The impact of thyroid disease on severity of motor symptoms in Croatian residents with de novo Parkinson’s disease

    I. Sarac, H. Sarac, F. Borovecki, I. Ivek, L. Bagaric Krakan, Z. Kresic, M. Iveta, T. Sukobljevic (Zagreb, Croatia)

    Objective: The goal of this study was to investigate the association between thyroid disease and severity of motor symptoms in Croatian residents with de novo…
  • 2022 International Congress

    Descriptive case studies of patients in their fifth consecutive year of treatment with ND0612

    A. Espay, A. Ellenbogen, T. Gurevich, R. Case, L. Adar, T. Yardeni, L. Salin (Cincinnati, USA)

    Objective: To describe the long-term experience of three individual patients receiving subcutaneous (SC) levodopa/carbidopa infusion with ND0612 in an open-label clinical safety study. Background: ND0612…
  • 2022 International Congress

    CCL5 promotes Th17 migrating into SNpc by promoting Th17 proportion increase and LFA-1 expression

    XZ. Xue (WuHan, China)

    Objective: To explore the specific pathway by which CCL5 induces Th17 cells migrating into substantia nigra pars compacta (SNpc) to aggravate Parkinson's disease (PD). Background:…
  • 2022 International Congress

    Blood-derived α-synuclein from Parkinson´s disease patients is able to seed pathology

    A. Kluge, J. Bunk, E. Schäffer, H. Knacke, A. Drobny, W. Xiang, R. Lucius, P. Arnold, F. Zunke, D. Berg (Kiel, Germany)

    Objective: To identify seeding capacities of soluble α-synuclein (α-syn) conformers derived from neuronal extracellular vesicles (NEs) from Parkinson´s disease (PD) patients. Background: PD pathology is…
  • « Previous Page
  • 1
  • …
  • 202
  • 203
  • 204
  • 205
  • 206
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Movement disorders in chronic obstructive pulmonary disease (COPD); the effect of pulmonary disease to brain
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley